CareDx (NASDAQ:CDNA) CEO John Walter Hanna, Jr. Sells 10,282 Shares

CareDx, Inc. (NASDAQ:CDNA) CEO John Walter Hanna, Jr. sold 10,282 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $21.12, for a total transaction of $217,155.84. Following the sale, the chief executive officer directly owned 676,475 shares in the company, valued at $14,287,152. This represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CareDx Stock Performance

Shares of NASDAQ CDNA opened at $21.29 on Tuesday. The firm has a market cap of $1.09 billion, a P/E ratio of -53.23 and a beta of 2.54. CareDx, Inc. has a 1 year low of $10.96 and a 1 year high of $23.24. The firm’s 50 day moving average price is $18.31 and its 200 day moving average price is $17.96.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.12). CareDx had a negative net margin of 5.65% and a negative return on equity of 6.50%. The business had revenue of $108.39 million during the quarter, compared to analyst estimates of $102.76 million. During the same quarter last year, the firm posted $0.18 earnings per share. The company’s revenue was up 25.2% on a year-over-year basis. As a group, equities analysts predict that CareDx, Inc. will post -0.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CDNA. BTIG Research raised their price target on CareDx from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings lowered shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, February 27th. Wall Street Zen cut shares of CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Craig Hallum lowered shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price target for the company. in a research report on Tuesday, January 6th. Finally, Wells Fargo & Company increased their price target on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $27.60.

Institutional Trading of CareDx

A number of institutional investors have recently modified their holdings of the company. Deerfield Management Company L.P. acquired a new position in CareDx during the third quarter valued at approximately $31,857,000. Braidwell LP acquired a new stake in shares of CareDx in the third quarter worth $31,738,000. Boston Partners raised its stake in shares of CareDx by 2,776.5% in the 4th quarter. Boston Partners now owns 901,929 shares of the company’s stock valued at $16,994,000 after acquiring an additional 870,574 shares during the period. Bamco Inc. NY raised its stake in shares of CareDx by 29.5% in the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company’s stock valued at $45,876,000 after acquiring an additional 719,523 shares during the period. Finally, Amova Asset Management Americas Inc. lifted its holdings in shares of CareDx by 40.8% during the 3rd quarter. Amova Asset Management Americas Inc. now owns 1,740,064 shares of the company’s stock valued at $25,283,000 after acquiring an additional 504,473 shares in the last quarter.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.